Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Krystal Biotech, Inc.KRYS · Entity 3500 | Director | September 14, 2026 | September 17, 2026 |
| Tectonic Therapeutic, Inc.AVRO · Entity 5328 | Chief Scientific Officer | June 10, 2021 | June 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Krystal Biotech, Inc.
Report date September 14, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $340.03 · Expires 2036-09-13 | Direct | 1,187 |
Reported balance
After 2026-09-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-14 · Grant · Acquired 1,187 · Balance 1,187 F1: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 471 |
Reported balance
After 2026-09-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-14 · Grant · Acquired 471 · Balance 471 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
Tectonic Therapeutic, Inc.
Report date June 10, 2021 · Filed June 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.63 · Expires 2031-06-09 | Direct | 125,000 |
Reported balance
After 2021-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-10 · Grant · Acquired 125,000 · Balance 125,000 F1: 50% of the shares shall vest and become exercisable on June 10, 2023, and the remaining 50% shall vest and become exercisable on June 10, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of the shares shall vest and become exercisable on June 10, 2023, and the remaining 50% shall vest and become exercisable on June 10, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 17, 2026 00:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantRestricted Stock Units · Derivative | 471 | $0.00 | $0.00 |
DisclosureSEC source: 0001836440-26-000002 · wk-form4_1789603304.xml · derivative · entry 2 Mason Christopher · CIK 0001836440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471 Underlying: Common Stock · 471 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. F3 · derivative.expiration_date: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. Read SEC document |
| September 14, 2026 Filed Sep 17, 2026 00:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 1,187 | $0.00 Strike: $340.03 | $0.00 |
DisclosureSEC source: 0001836440-26-000002 · wk-form4_1789603304.xml · derivative · entry 1 Mason Christopher · CIK 0001836440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,187 Underlying: Common Stock · 1,187 shares Expires 2036-09-13 F1 · derivative.exercise_date: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. Read SEC document |
| June 30, 2025 Filed Jun 30, 2025 22:09 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $137.46 | $0.00 |
DisclosureSEC source: 0001836440-25-000003 · wk-form4_1751321359.xml · derivative · entry 1 Mason Christopher · CIK 0001836440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2025 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 30, 2024 Filed Jul 1, 2024 23:32 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $183.64 | $0.00 |
DisclosureSEC source: 0001836440-24-000004 · wk-form4_1719876723.xml · derivative · entry 1 Mason Christopher · CIK 0001836440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2024 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:24 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $117.40 | $0.00 |
DisclosureSEC source: 0001711279-23-000053 · wk-form4_1688415856.xml · derivative · entry 1 Mason Christopher · CIK 0001836440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2033-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2023 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:09 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $65.66 | $0.00 |
DisclosureSEC source: 0001711279-22-000036 · wf-form4_165670614389935.xml · derivative · entry 1 Mason Christopher · CIK 0001836440 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2032-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2022 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 15:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $68.00 | $0.00 |
DisclosureSEC source: 0001711279-21-000016 · wf-form4_162523981348902.xml · derivative · entry 1 Mason Christopher · CIK 0001836440 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2031-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2021 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 22:03 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019838 · form4.xml · derivative · entry 1 Mason Christopher · CIK 0001836440 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 50% of the shares shall vest and become exercisable on June 10, 2023, and the remaining 50% shall vest and become exercisable on June 10, 2024. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:07 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 13,600 | $0.00 Strike: $59.42 | $0.00 |
DisclosureSEC source: 0000899243-21-000410 · doc4.xml · derivative · entry 1 Mason Christopher · CIK 0001836440 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,600 Underlying: Common Stock · 13,600 shares Expires 2031-01-04 F1 · derivative.exercise_date: The options were awarded on January 4, 2021 and vest in equal amounts over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.